Placebo News and Research

RSS

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

A research study conducted by Dr. Jesus Lovera, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has found that the herbal supplement Ginkgo biloba does not improve cognitive function in patients with Multiple Sclerosis (MS).

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Dengue vaccine breakthrough

Results of the first ever trial to show that a safe and effective dengue vaccine may be possible are published Online First in The Lancet.

11 Sep 2012

Polysaccharopeptide improves survival in dogs with hemangiosarcoma

Dogs with hemangiosarcoma that were treated with a compound derived from the Coriolus versicolor mushroom had the longest survival times ever reported for dogs with the disease.

11 Sep 2012

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of LL-37 for the treatment of patients with hard-to-heal venous leg ulcers.

11 Sep 2012

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).

11 Sep 2012

'No malignancy risk' with biologic response modifiers

Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.

10 Sep 2012

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Scientists used genetic sequencing to discover new evidence that the first vaccine shown to prevent HIV infection in people also affected the viruses in those who did become infected. Viruses with two genetic "footprints" were associated with greater vaccine efficacy. The results were published today in the online edition of the journal Nature.

10 Sep 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

TauRx initiates LMTX Phase 3 trial in Pick's Disease

TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.

10 Sep 2012

Antibiotic treatment more effective than placebo in patients with mild-to-moderate COPD

Antibiotic treatment with amoxicillin/clavulanate improves moderate exacerbations in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) and significantly prolongs the time between exacerbations, according to a new study from researchers in Spain.

10 Sep 2012

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients who have already received one prior chemotherapy regimen, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

7 Sep 2012

Vitamin D supplements have unintended lipid consequences

Correcting vitamin D levels in individuals at risk for cardiovascular disease may have detrimental effects on their lipid profiles, report researchers.

6 Sep 2012

Constipation drug may bring US patients relief

The US Food and Drug Administration has approved linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.

6 Sep 2012

Hopes dashed for ginkgo biloba in Alzheimer’s disease

The GuidAge trial of ginkgo biloba extract in people with evidence of memory problems confirms that the treatment does not reduce their risk for progression to Alzheimer’s disease.

6 Sep 2012

Alzheimer’s disease is not prevented by ginkgo biloba

Ginkgo biloba extract does not significantly reduce the likelihood of diagnosis of Alzheimer’s disease in older people, according to the results of the largest ever Alzheimer’s prevention study in Europe, published in The Lancet Neurology.

6 Sep 2012

Injecting capsule with heat-generating cells reduces abdominal and belly fat in mice

The injection of a tiny capsule containing heat-generating cells into the abdomens of mice led those animals to burn abdominal fat and initially lose about 20 percent of belly fat after 80 days of treatment.

6 Sep 2012

FDA continues review of Salix’s Crofelemer new drug application

Napo Pharmaceuticals, Inc. was informed today that the Food and Drug Administration is continuing its review of the new drug application seeking approval of crofelemer for the treatment of chronic diarrhea in people living with HIV/AIDS on anti-retroviral therapy.

6 Sep 2012

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center.

6 Sep 2012

Placebo News and Research

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Dengue vaccine breakthrough

Polysaccharopeptide improves survival in dogs with hemangiosarcoma

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

'No malignancy risk' with biologic response modifiers

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Phase III data for Suvorexant, an investigational insomnia medicine, announced

TauRx initiates LMTX Phase 3 trial in Pick's Disease

Antibiotic treatment more effective than placebo in patients with mild-to-moderate COPD

Adding bavituximab to docetaxel doubles overall survival in late-stage NS-NSCLC patients

Vitamin D supplements have unintended lipid consequences

Constipation drug may bring US patients relief

Hopes dashed for ginkgo biloba in Alzheimer’s disease

Alzheimer’s disease is not prevented by ginkgo biloba

Injecting capsule with heat-generating cells reduces abdominal and belly fat in mice

FDA continues review of Salix’s Crofelemer new drug application

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News